Bioptik Technology (4161) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioptik Technology (4161) has a cash flow conversion efficiency ratio of 0.055x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.21 Million ≈ $1.68 Million USD) by net assets (NT$974.69 Million ≈ $30.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bioptik Technology (4161) balance sheet quality index to measure how much of total assets are equity-financed.
Bioptik Technology - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Bioptik Technology's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Bioptik Technology earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Bioptik Technology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioptik Technology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
eHealth Inc
NASDAQ:EHTH
|
0.037x |
|
Biokarpet S.A.
AT:BIOKA
|
0.168x |
|
Better Life Group Co Ltd
TW:1805
|
-0.011x |
|
Poh Huat Resources Holdings
KLSE:7088
|
0.049x |
|
Pembangunan Jaya Ancol Tbk
JK:PJAA
|
0.107x |
|
K Seng Seng Corporation Bhd
KLSE:5192
|
0.144x |
|
Tidehold Development Co Ltd
TW:9902
|
0.079x |
|
Alpha Holdings Inc
KQ:117670
|
-0.065x |
Annual Cash Flow Conversion Efficiency for Bioptik Technology (2017–2025)
The table below shows the annual cash flow conversion efficiency of Bioptik Technology from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Bioptik Technology market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$974.69 Million ≈ $30.71 Million |
NT$59.99 Million ≈ $1.89 Million |
0.062x | -64.92% |
| 2024-12-31 | NT$905.27 Million ≈ $28.52 Million |
NT$158.82 Million ≈ $5.00 Million |
0.175x | -29.79% |
| 2023-12-31 | NT$824.15 Million ≈ $25.97 Million |
NT$205.95 Million ≈ $6.49 Million |
0.250x | +225.81% |
| 2022-12-31 | NT$717.83 Million ≈ $22.62 Million |
NT$55.06 Million ≈ $1.73 Million |
0.077x | +229.45% |
| 2021-12-31 | NT$694.54 Million ≈ $21.88 Million |
NT$-41.15 Million ≈ $-1.30 Million |
-0.059x | -763.13% |
| 2020-12-31 | NT$735.66 Million ≈ $23.18 Million |
NT$6.57 Million ≈ $207.09K |
0.009x | -83.27% |
| 2019-12-31 | NT$768.38 Million ≈ $24.21 Million |
NT$41.03 Million ≈ $1.29 Million |
0.053x | +3.64% |
| 2018-12-31 | NT$811.73 Million ≈ $25.57 Million |
NT$41.83 Million ≈ $1.32 Million |
0.052x | +314.97% |
| 2017-12-31 | NT$887.42 Million ≈ $27.96 Million |
NT$11.02 Million ≈ $347.16K |
0.012x | -- |
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also p… Read more